전립선암 핵의학 진단 시장 : 방사성 의약품, 검사법, 적응증, 최종 사용자별 예측(2026-2032년)

The Prostate Cancer Nuclear Medicine Diagnostics Market is projected to grow by USD 3.12 billion at a CAGR of 13.17% by 2032.

Prostate cancer nuclear medicine diagnostics are moving from a specialist imaging option to a core clinical decision tool in oncology. The field is anchored by positron emission tomography and single-photon emission computed tomography used to localize disease, characterize recurrence, guide radioligand therapy eligibility, and improve confidence in staging. Demand is reinforced by the global prostate cancer burden; IARC GLOBOCAN 2022 estimated more than 1.46 million new prostate cancer cases worldwide, making it one of the most frequently diagnosed cancers in men.

PSMA-targeted PET imaging has become the defining growth catalyst. Gallium-68 and fluorine-18 PSMA radiotracers have demonstrated higher lesion detection than conventional CT, bone scan, or older choline-based imaging in many clinical scenarios, particularly biochemical recurrence and high-risk primary staging. As guidelines from major oncology, urology, and nuclear medicine bodies increasingly recognize PSMA PET, healthcare systems are prioritizing cyclotron capacity, generator access, radiopharmacy networks, and integrated PET/CT workflows.

Transformative Shifts in the Diagnostic Landscape

The landscape is being reshaped by the transition from anatomy-led imaging to molecular, target-specific diagnostics. PSMA PET/CT is expanding because it can identify nodal, bone, and soft-tissue disease at low tumor burden, supporting earlier treatment decisions and more precise patient selection. Fluorine-18 tracers are also changing distribution economics because their longer half-life enables broader regional delivery than gallium-68 in many settings.

Another major shift is the diagnostic-therapeutic convergence between PSMA imaging and radioligand therapy. Nuclear medicine departments are increasingly positioned within prostate cancer tumor boards, where imaging results influence surgery, radiation planning, systemic therapy sequencing, and theranostic eligibility. This integration is pushing hospitals, imaging technology providers, and radiopharmaceutical developers to build scalable quality systems, standardized interpretation protocols, and resilient isotope supply chains.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to alter how prostate cancer nuclear medicine diagnostics are acquired, interpreted, and operationalized. AI-enabled reconstruction can reduce image noise and may support shorter scan times or lower administered activity when validated under local protocols. Computer-aided lesion detection, automated segmentation, SUV quantification, and whole-body tumor burden measurement are improving reproducibility in PSMA PET workflows.

The cumulative impact is strongest when AI connects imaging with clinical context. Radiomics and machine learning models are being evaluated to predict disease aggressiveness, therapy response, and progression risk by combining PET signal, CT or MRI features, PSA kinetics, Gleason score, and treatment history. Industry leaders should treat AI as a regulated clinical decision-support layer, requiring transparent validation, bias monitoring, cybersecurity controls, and integration with PACS, RIS, oncology information systems, and electronic health records.

Key Regional Insights Across Major Markets

North America remains a leading region for prostate cancer nuclear medicine diagnostics due to FDA-cleared PSMA PET agents, high PET/CT installed capacity, strong academic nuclear medicine programs, and established reimbursement pathways. The United States has accelerated adoption through multiple approved PSMA-targeted tracers, while Canada benefits from centralized cancer care networks and growing provincial access, although availability still varies by geography.

Europe is a mature and innovation-rich region, supported by early PSMA PET adoption, strong university hospital infrastructure, and coordinated clinical research. The European Union benefits from cross-border regulatory harmonization, while the United Kingdom, Germany, France, Italy, and Spain continue to expand evidence-based use in staging and recurrence. Asia-Pacific is one of the fastest-evolving opportunity areas, with Japan, Australia, South Korea, China, and India investing in PET capacity, cyclotron networks, and oncology diagnostics to address rising cancer demand and aging-population needs.

Latin America is gaining momentum through Brazil and Mexico, where major urban centers are adopting PET-based prostate cancer imaging despite uneven reimbursement and radiopharmaceutical access. The Middle East, particularly GCC health systems, is investing in premium oncology infrastructure, specialist hospitals, and medical tourism-ready diagnostics. Africa remains underpenetrated, with access concentrated in select centers such as South Africa and North African urban hubs, creating long-term demand for regional radiopharmacy development, workforce training, and public-private investment.

Key Group Insights for Strategic Market Prioritization

ASEAN is characterized by rapid healthcare modernization but uneven nuclear medicine capacity, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines moving at different speeds in PET/CT access, tracer supply, and reimbursement. The GCC is one of the most attractive high-investment clusters because Saudi Arabia, the UAE, Qatar, Kuwait, Bahrain, and Oman are expanding oncology centers, radiology infrastructure, and specialist medical workforce capacity.

The European Union offers a strong platform for standardized adoption because regulatory alignment, multicenter trials, and nuclear medicine society-led clinical practice norms support scalable PSMA PET implementation. BRICS markets combine large prostate cancer patient populations with diverse infrastructure maturity: China and India are expanding quickly, Brazil and Russia have regional centers of excellence, and South Africa provides an important gateway for African nuclear medicine development.

G7 countries represent the deepest commercial base, with high diagnostic spending, advanced PET infrastructure, and strong pharmaceutical innovation in the United States, Canada, Japan, Germany, France, Italy, and the United Kingdom. NATO countries add relevance through resilient medical isotope supply chains, radiological safety standards, interoperable health systems, and public-sector hospital networks that can influence procurement and emergency preparedness in nuclear medicine.

Key Country Insights for Prostate Cancer Imaging Demand

The United States is the most commercially advanced country for prostate cancer nuclear medicine diagnostics, supported by FDA approvals for PSMA PET agents, high clinical awareness, broad PET/CT availability, and strong private and public payer engagement. Canada is expanding access through cancer agency-led models and provincial pathways, while Mexico is developing demand in private hospital networks and major metropolitan centers. Brazil leads Latin American scale, with Sao Paulo and other large cities supporting advanced PET services.

In Europe, the United Kingdom is strengthening PSMA PET use through specialist cancer pathways, Germany remains a global leader in nuclear medicine research and theranostics, and France benefits from sophisticated academic hospital networks. Italy and Spain continue to increase utilization in recurrence and staging, while Russia maintains PET infrastructure in major cities despite broader market constraints.

China is expanding PET/CT capacity and domestic radiopharmaceutical capabilities, while India offers high-volume long-term potential as oncology infrastructure grows beyond major cities. Japan benefits from advanced imaging quality standards and aging-population demand, Australia is a strong early adopter of PSMA PET evidence generation, and South Korea combines high technology adoption with sophisticated hospital systems and strong oncology diagnostics capacity.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize scalable radiopharmaceutical access, including diversified isotope sourcing, validated cold-chain logistics, and partnerships with cyclotron operators, generator suppliers, and regional radiopharmacies. Commercial success increasingly depends on reliable same-day availability, standardized quality control, radiation safety compliance, and clear scheduling integration with PET/CT departments.

Providers and manufacturers should build evidence packages that connect PSMA PET results to measurable outcomes such as reduced unnecessary procedures, improved radiation planning, earlier recurrence detection, and better selection for radioligand therapy. Organizations should also invest in clinician education for urologists, radiation oncologists, medical oncologists, and nuclear medicine physicians to accelerate appropriate referrals.

Technology providers should embed AI-enabled quantification, structured reporting, and interoperability into imaging platforms while ensuring compliance with medical device regulations and data privacy rules. Market entrants should tailor pricing, reimbursement, and distribution strategies by country maturity rather than applying a single global launch model.

Research Methodology and Evidence Framework

This executive summary is based on triangulated secondary research and market intelligence methods suitable for healthcare technology and radiopharmaceutical analysis. The evidence base includes publicly available regulatory records, oncology and nuclear medicine guidelines, peer-reviewed clinical literature, cancer epidemiology databases, government health statistics, reimbursement references, and radiopharmaceutical access indicators.

Data validation relies on cross-checking clinical adoption signals against tracer approvals, PET infrastructure availability, radiopharmacy capabilities, guideline inclusion, and regional oncology investment trends. Qualitative interpretation is supported by analysis of hospital workflow requirements, isotope logistics, competitive positioning, payer considerations, and regulatory requirements. Findings are framed to support strategic planning and should be periodically updated as approvals, reimbursement policies, and clinical evidence evolve.

Conclusion and Strategic Outlook

Prostate cancer nuclear medicine diagnostics are entering a sustained expansion phase driven by PSMA-targeted imaging, growing PET infrastructure, radiotheranostic integration, and rising demand for precision oncology. The sector is no longer defined only by scan volume; it is increasingly shaped by tracer logistics, evidence-based clinical pathways, quantitative imaging, and multidisciplinary adoption.

Organizations that combine dependable radiopharmaceutical supply, regulatory-grade data, AI-enabled workflow efficiency, and region-specific commercialization will be best positioned to capture value. As prostate cancer care shifts toward earlier detection of actionable disease and better treatment personalization, nuclear medicine diagnostics will remain a strategic pillar of the global oncology ecosystem.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Prostate Cancer Nuclear Medicine Diagnostics Market, by Radiopharmaceutical

• 7.1. 11C Choline
• 7.2. 18F DcfpyL
• 7.3. 18F Fluciclovine
• 7.4. 68Ga Psma
• 7.5. Emerging Agents
  • 7.5.1. 18F Psma 1007
  • 7.5.2. 64Cu Psma

8. Prostate Cancer Nuclear Medicine Diagnostics Market, by Modality

• 8.1. Pet
  • 8.1.1. Digital Pet
  • 8.1.2. Time Of Flight Pet
• 8.2. Spect
  • 8.2.1. Conventional Spect
  • 8.2.2. Spect Ct

9. Prostate Cancer Nuclear Medicine Diagnostics Market, by Indication

• 9.1. Biochemical Recurrence Detection
• 9.2. Initial Staging
• 9.3. Treatment Monitoring

10. Prostate Cancer Nuclear Medicine Diagnostics Market, by End User

• 10.1. Academic Research Institute
• 10.2. Diagnostic Center
• 10.3. Hospital

11. Prostate Cancer Nuclear Medicine Diagnostics Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Prostate Cancer Nuclear Medicine Diagnostics Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Prostate Cancer Nuclear Medicine Diagnostics Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Bayer AG
• 15.2. Blue Earth Diagnostics Ltd.
• 15.3. Cardinal Health, Inc.
• 15.4. Curium Pharma
• 15.5. Eckert & Ziegler SE
• 15.6. GE HealthCare Technologies Inc.
• 15.7. IBA Radiopharma Solutions
• 15.8. Jubilant Pharmova Limited
• 15.9. Lantheus Holdings, Inc.
• 15.10. Novartis AG
• 15.11. Siemens Healthineers AG
• 15.12. Telix Pharmaceuticals Limited